Kevin D Stuart, MD
Gastroenterology · Gilroy
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 25
- 5 carriers
- Office
- 1
On the public record
- Owns Morgan Hill Surgery Center, LP: Accreditation Lapsed
Offices
1 location
Looking this up.
Hospitals listed: B21550 · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
25 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Stuart’s office at (408) 847-1311 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
25 of 25 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G71509 · Current
Licensed to practise in California · since 1991 · expires 2029-01-31 · State University of New York, Downstate Medical Center College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Morgan Hill Surgery Center, LPAmbulatory Surgery Center · Morgan Hill, CA16.6% owner · accredited by AAAHCAccreditation Lapsed1 inspection · last 2012-08-03
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$8,573
Medicare paid this office $8,573 for 41 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $4,232 | $124 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 17 | More than 48% of doctors who do this |
Who their Medicare patients are
41 Original Medicare patients in 2024. Average age 72 · Women 46% · Also on Medicaid 49% · Health risk score 1.94. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 44% · Coronary heart disease 29% · Heart failure 29% · Depression 29% · Chronic kidney disease 27%.
The office billed $73,809, Medicare allowed $11,663 and paid $8,573; for 75 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 41 | 75 | 72 | 1.94 | $73,809 | $8,573 |
| 2023 | 77 | 154 | 72 | 2.77 | $154,994 | $19,328 |
| 2022 | 380 | 949 | 74 | 1.20 | $655,615 | $95,529 |
| 2021 | 393 | 1,009 | 74 | 1.22 | $670,054 | $104,492 |
| 2020 | 370 | 892 | 74 | 1.33 | $577,284 | $83,386 |
| 2019 | 420 | 1,159 | 73 | 1.15 | $787,247 | $110,525 |
| 2018 | 381 | 1,093 | 74 | 1.17 | $703,187 | $100,156 |
| 2017 | 463 | 1,322 | 73 | 1.22 | $920,734 | $131,336 |
| 2016 | 492 | 1,279 | 73 | 1.21 | $982,439 | $147,429 |
| 2015 | 468 | 1,205 | 73 | 1.23 | $950,471 | $149,603 |
| 2014 | 499 | 1,323 | 72 | 1.13 | $1,016,289 | $166,575 |
| 2013 | 454 | 1,201 | 72 | 1.15 | $909,669 | $149,685 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Critical care, first 30-74 minutes | 42 | $8,643 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,248 | $66 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $962 | $60 |
2022: 15 services
| Short return visit (20+ min) | 180 | $20,882 | $76 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 77 | $15,748 | $199 |
| Critical care, first 30-74 minutes | 52 | $8,782 | $163 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 30 | $5,893 | $196 |
| Return visit (30+ min) | 36 | $5,792 | $111 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 26 | $5,196 | $200 |
| Destruction of internal hemorrhoids using heat | 17 | $4,846 | $186 |
| New patient visit (30+ min) | 37 | $2,868 | $78 |
| Biopsy of large bowel using a flexible endoscope | 19 | $2,572 | $135 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 39 | $2,432 | $62 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 19 | $2,275 | $120 |
| Diagnostic exam of large bowel using a flexible endoscope | 15 | $2,099 | $140 |
| New patient visit (15+ min) | 30 | $1,746 | $58 |
| Short return visit | 24 | $1,457 | $47 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 157 | $651 | $4 |
2021: 15 services
| Short return visit (20+ min) | 187 | $21,499 | $77 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 67 | $14,042 | $210 |
| Critical care, first 30-74 minutes | 56 | $10,833 | $178 |
| Return visit (30+ min) | 49 | $7,837 | $115 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 28 | $5,695 | $203 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 27 | $5,495 | $204 |
| New patient visit (30+ min) | 59 | $5,225 | $89 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 54 | $4,852 | $88 |
| Destruction of internal hemorrhoids using heat | 16 | $3,812 | $212 |
| Biopsy of large bowel using a flexible endoscope | 19 | $2,794 | $147 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,952 | $163 |
| New patient visit (15+ min) | 29 | $1,620 | $56 |
| Short return visit | 19 | $1,117 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,061 | $59 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 161 | $733 | $4 |
2020: 17 services
| Short return visit (20+ min) | 167 | $12,545 | $54 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 44 | $9,228 | $210 |
| Critical care, first 30-74 minutes | 41 | $8,062 | $187 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 35 | $7,137 | $204 |
| Return visit (30+ min) | 63 | $6,573 | $81 |
| Removal of external hemorrhoids by rubber banding | 13 | $5,247 | $262 |
| Destruction of internal hemorrhoids using heat | 20 | $5,045 | $194 |
| New patient visit (30+ min) | 59 | $4,720 | $80 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 45 | $3,661 | $81 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $3,102 | $207 |
| Biopsy of large bowel using a flexible endoscope | 19 | $2,764 | $145 |
| Diagnostic exam of large bowel using a flexible endoscope | 18 | $2,688 | $149 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 15 | $2,154 | $135 |
| New patient visit (15+ min) | 36 | $1,960 | $54 |
| New patient visit (45+ min) | 12 | $1,617 | $135 |
| Short return visit | 13 | $651 | $41 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 133 | $596 | $4 |
2019: 17 services
| Short return visit (20+ min) | 185 | $17,199 | $60 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 62 | $12,353 | $199 |
| Return visit (30+ min) | 85 | $11,721 | $90 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 45 | $8,759 | $195 |
| Critical care, first 30-74 minutes | 40 | $8,071 | $175 |
| New patient visit (30+ min) | 72 | $5,960 | $83 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 70 | $5,858 | $83 |
| Destruction of internal hemorrhoids using heat | 20 | $4,101 | $186 |
| Biopsy of large bowel using a flexible endoscope | 28 | $3,849 | $137 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 18 | $3,526 | $196 |
| Diagnostic exam of large bowel using a flexible endoscope | 21 | $2,998 | $143 |
| New patient visit (45+ min) | 14 | $2,035 | $145 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 14 | $1,896 | $135 |
| New patient visit (15+ min) | 29 | $1,596 | $55 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,455 | $97 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 179 | $776 | $4 |
| Short return visit | 16 | $667 | $37 |
2018: 16 services
| Short return visit (20+ min) | 159 | $15,282 | $57 |
| Return visit (30+ min) | 97 | $12,236 | $84 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 50 | $10,270 | $205 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 45 | $8,733 | $194 |
| Critical care, first 30-74 minutes | 39 | $7,224 | $181 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 70 | $6,436 | $89 |
| New patient visit (30+ min) | 62 | $5,155 | $83 |
| Destruction of internal hemorrhoids using heat | 20 | $4,203 | $183 |
| Biopsy of large bowel using a flexible endoscope | 20 | $2,973 | $149 |
| New patient visit (45+ min) | 22 | $2,543 | $116 |
| Diagnostic exam of large bowel using a flexible endoscope | 17 | $2,154 | $127 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 17 | $2,131 | $125 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,211 | $87 |
| New patient visit (15+ min) | 22 | $1,105 | $50 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 172 | $741 | $4 |
| Short return visit | 12 | $511 | $36 |
2017: 18 services
| Short return visit (20+ min) | 171 | $17,110 | $60 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 84 | $15,758 | $188 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 71 | $14,956 | $211 |
| Return visit (30+ min) | 109 | $14,419 | $90 |
| Critical care, first 30-74 minutes | 45 | $9,131 | $186 |
| Destruction of internal hemorrhoids using heat | 33 | $8,028 | $182 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 71 | $7,247 | $99 |
| New patient visit (30+ min) | 61 | $5,282 | $87 |
| Removal of external hemorrhoids by rubber banding | 15 | $4,347 | $229 |
| Diagnostic exam of large bowel using a flexible endoscope | 25 | $3,942 | $158 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $2,656 | $98 |
| New patient visit (45+ min) | 17 | $2,336 | $137 |
| Biopsy of large bowel using a flexible endoscope | 16 | $1,850 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,746 | $60 |
| New patient visit (15+ min) | 20 | $1,151 | $58 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 217 | $1,022 | $5 |
| Short return visit | 17 | $716 | $36 |
| Dilation of esophagus with a guide wire | 13 | $523 | $40 |
2016: 19 services
| Short return visit (20+ min) | 212 | $20,718 | $62 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 97 | $20,138 | $205 |
| Return visit (30+ min) | 119 | $17,074 | $92 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 57 | $12,151 | $210 |
| Imaging of digestive tract done from the inside of the digestive tract | 11 | $9,674 | $879 |
| Removal of external hemorrhoids by rubber banding | 19 | $7,948 | $248 |
| New patient visit (30+ min) | 92 | $7,818 | $85 |
| Destruction of internal hemorrhoids using heat | 30 | $6,988 | $189 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 62 | $6,580 | $104 |
| New patient visit (45+ min) | 46 | $6,072 | $132 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 41 | $4,447 | $106 |
| Critical care, first 30-74 minutes | 25 | $4,197 | $168 |
| Diagnostic exam of large bowel using a flexible endoscope | 16 | $2,769 | $163 |
| New patient visit (15+ min) | 50 | $2,602 | $52 |
| Control of bleeding of upper large bowel using a flexible endoscope | 11 | $2,572 | $234 |
| Biopsy of large bowel using a flexible endoscope | 24 | $2,497 | $104 |
| Short return visit | 29 | $1,468 | $36 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,134 | $63 |
| Dilation of esophagus with a guide wire | 22 | $902 | $41 |
2015: 17 services
| Short return visit (20+ min) | 199 | $19,319 | $59 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 68 | $16,365 | $234 |
| Return visit (30+ min) | 105 | $13,869 | $92 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 51 | $11,384 | $223 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 75 | $8,354 | $110 |
| New patient visit (45+ min) | 60 | $8,024 | $134 |
| Removal of external hemorrhoids by rubber banding | 16 | $7,701 | $248 |
| New patient visit (30+ min) | 80 | $7,139 | $89 |
| Destruction of internal hemorrhoids using heat | 26 | $5,959 | $192 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 26 | $5,800 | $223 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,363 | $163 |
| Diagnostic exam of large bowel using a flexible endoscope | 27 | $4,766 | $177 |
| Biopsy of large bowel using a flexible endoscope | 26 | $4,474 | $172 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | $3,732 | $110 |
| New patient visit (15+ min) | 27 | $1,680 | $62 |
| Short return visit | 27 | $1,216 | $37 |
| Dilation of esophagus with a guide wire | 27 | $1,184 | $42 |
2014: 20 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 87 | $22,849 | $263 |
| Short return visit (20+ min) | 217 | $21,354 | $62 |
| Return visit (30+ min) | 95 | $12,093 | $88 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 99 | $10,644 | $104 |
| Imaging of digestive tract done from the inside of the digestive tract | 11 | $10,080 | $916 |
| Removal of external hemorrhoids by rubber banding | 15 | $9,822 | $246 |
| New patient visit (30+ min) | 103 | $9,622 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $8,709 | $171 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 36 | $8,502 | $236 |
| Destruction of internal hemorrhoids using heat | 35 | $7,964 | $177 |
| New patient visit (45+ min) | 47 | $6,734 | $143 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 27 | $6,335 | $235 |
| Diagnostic exam of large bowel using a flexible endoscope | 33 | $6,263 | $190 |
| Biopsy of large bowel using a flexible endoscope | 28 | $5,420 | $194 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $2,983 | $107 |
| New patient visit (15+ min) | 37 | $2,141 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $1,922 | $64 |
| Short return visit | 41 | $1,453 | $33 |
| Dilation of esophagus with a guide wire | 18 | $782 | $41 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 23 | $211 | $9 |
2013: 18 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 79 | $19,534 | $244 |
| Short return visit (20+ min) | 176 | $16,874 | $62 |
| Return visit (30+ min) | 115 | $14,301 | $89 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 89 | $11,485 | $126 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 39 | $9,448 | $242 |
| Destruction of internal hemorrhoids using heat | 34 | $8,580 | $187 |
| New patient visit (45+ min) | 53 | $7,802 | $147 |
| New patient visit (30+ min) | 83 | $7,662 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,228 | $168 |
| Diagnostic exam of large bowel using a flexible endoscope | 25 | $4,494 | $180 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $3,860 | $125 |
| New patient visit (15+ min) | 60 | $3,599 | $60 |
| Biopsy of large bowel using a flexible endoscope | 18 | $3,324 | $185 |
| Control of bleeding of upper large bowel using a flexible endoscope | 11 | $3,236 | $294 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,803 | $90 |
| Short return visit | 42 | $1,580 | $36 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,001 | $63 |
| Dilation of esophagus with a guide wire | 18 | $792 | $44 |
Medicaid work
$1,086 in 2024
Medicaid paid $1,086 for 102 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Service | 12 | $535 |
| New patient visit (45+ min) | 12 | $456 |
| Service | 12 | $96 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 31 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 35 | $0 |
| 2024 | 102 | 5 | 19 | $1,086 |
| 2023 | 52 | 3 | 16 | $30 |
See the largest Medicaid services in earlier years
2023
| Service | 12 | $30 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 12 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 28 | $0 |
Money from drug and device companies
$4,563 in 2022
| 2022 | 5 | 17 | $4,000 | $4,563 |
| 2021 | 3 | 4 | None | $75 |
| 2020 | 1 | 2 | None | $23 |
| 2019 | 8 | 11 | $13 | $253 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Pillcam | $4,470 | 12 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $41 | 2 payments
|
| Janssen Biotech | Remicade | $22 | 1 payment
|
| Medivators | Cer-2 Optima | $17 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $13 | 1 payment
|
See all 17 published payments
| Medtronic | Consulting · 2022-09-30 | None | $3,500 |
| Medtronic | Travel · 2022-09-20 | Pillcam | $110 |
| Medtronic | Meals · 2022-09-20 | Pillcam | $36 |
| Medtronic | Meals · 2022-09-20 | Pillcam | $20 |
| Medtronic | Meals · 2022-09-20 | Pillcam | $24 |
| Medtronic | Meals · 2022-09-20 | Pillcam | $45 |
| Medtronic | Meals · 2022-09-20 | Pillcam | $38 |
| Medtronic | Meals · 2022-09-20 | Pillcam | $20 |
| Medtronic | Meals · 2022-09-20 | Pillcam | $61 |
| Medtronic | Meals · 2022-09-13 | Pillcam | $30 |
| Medtronic | Meals · 2022-09-13 | Pillcam | $87 |
| Janssen Biotech | Meals · 2022-07-07 | Remicade | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2022-06-28 | Entyvio | $19 |
| Merck Sharp & Dohme | Meals · 2022-03-08 | Dificid | $13 |
| Medivators | Meals · 2022-02-18 | Cer-2 Optima | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2022-02-15 | Entyvio | $22 |
| Medtronic | Consulting · 2022-01-09 | None | $500 |
See earlier years (2021, 2020, 2019)
2021: $75
| Micro-tech Endoscopy USA | All Products | $34 | 1 payment
|
| Celgene | Zeposia | $27 | 2 payments
|
| Alfasigma USA | Zelnorm | $13 | 1 payment
|
2020: $23
| Takeda Pharmaceuticals U.S.A. | Entyvio | $23 | 2 payments
|
2019: $253
| Braintree Laboratories | Suprep Bowel Prep | $107 | 2 payments
|
| Shionogi | Mulpleta | $39 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $34 | 2 payments
|
| AbbVie | Mavyret | $19 | 1 payment
|
| Vivus | Pancreaze | $15 | 1 payment
|
| Janssen Biotech | Stelara | $14 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $13 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2021 | Their institution | $81,833 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2025 | Their institution | $38,186 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2022 | Their institution | $33,440 |
| AstraZeneca Pharmaceuticals LP · A Phase 2b3 Randomized, Double Blind, Placebo Controlled Study To Evaluate the Safety and Efficacy of Cotadutide in Participants With Non Cirrhotic Non Alcoholic Steatohepatitis With Fibrosis · 2023 | Their institution | $23,677 |
| Eli Lilly and Company · A Phase 3 Multicenter Open Label Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2023 | Their institution | $20,225 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2024 | Their institution | $16,307 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2022 | Their institution | $12,338 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2020 | This clinician | $8,000 |
| AstraZeneca Pharmaceuticals LP · A Phase 2b3 Randomized, Double Blind, Placebo Controlled Study To Evaluate the Safety and Efficacy of Cotadutide in Participants With Non Cirrhotic Non Alcoholic Steatohepatitis With Fibrosis · 2024 | Their institution | $7,500 |
| Eli Lilly and Company · A Phase 3 Multicenter Randomized Double-Blind Placebo- and Active- Controlled Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2023 | Their institution | $5,247 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2024 | Their institution | $4 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1912966185
- Licence
- CA G71509California G71509: Current · expires 2029-01-31
- Trained
- State University of Ny Upstate Medical University, 1986
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 9460 No Name Uno, Suite 130, Gilroy, CA, 95020
- NPI first listed
- 2006-03-17
- NPI last updated
- 2013-07-23
This is when the NPI record was last certified, not a medical board exam.